AGP100-C01: A Phase 2a Trial to Investigate Safety, Tolerability and Exploratory Efficacy of AGP100 in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia

AGP100 - Agiana Pharmaceuticals

Feb 18, 2026